Do you think you need a #steroid sparing Rx in #polymyalgia #rheumatica? +data in #sarilumab w 14 wk ped taper. No diverticulitis, ?Stacking comparator grp to flare as past steroid tapering caused a flare. But that is an unmet need after long pred Rx Abst#1543 #ACR22 @RheumNow https://t.co/Q1bhYs7LEz

Intersting discussion post Plenary this AM - Agree w/RS that we should taper steroid - Is there a disease modifying benefit? I think not - When should this be used? Disagree w/RS, I would not use unless relapsing/refractory and requiring >10mg pred #ACR22 @RheumNow https://t.co/ylGXk2sca7

Study shows no progressive increase of MRI structural lesions in SI joints of health individuals with increasing age, including: Bone marrow edema, erosions, fat lesions Abs#2258 @RheumNow #ACR22 https://t.co/W2dkRCAPc4

SSc and DM/PM can cause disease related sexual dysfunction ➡️ consider pelvic floor PT Abstract #0940 #ACR22 @RheumNow 🧘‍♀️8 week PT program targeting pelvic floor exercises and MSK issues impacting sexual function 🧘Women experienced sig. improved sexual function and QOL

Ab1677 #ACR22 by @MaxKonigMD Chimeric autoAg T cell recepter (CATCR) reprogram T cells to selectively kill autoreactive B cells Model CATCR for APLS via B2GPI-CATCR T-cells eliminating anti-B2GP DI B cells, dose-dependent Model for SELECTIVE Rx in APLS/rheum disease @RheumNow https://t.co/jMpMu10phL

Very cool preclinical plenary @MaxKonigMD Instead of CAR-T to just CD19, created CATCRs that selectively kill specific B cells (beta2 glycoprotein expressing cells) Early days but super interesting possibilities - APS, SLE, AAV, & more? #ACR22 @rheumnow #ACRBest Abstr#1677 https://t.co/nS3YtR6wN9

#ACR22 highlights. #PMR May have Steroid sparing options. #tocilizumab abst#1106, #tofacitinib abst1107, #sarilumab #1676. Also previous #secukinumab ALL positive RCTs #ACRBest @RheumNow

Izmirly et al. HCQ crosses placenta but no evidence ocular toxicity in children at 5 years old by OCT @RheumNow #ACR22 Abstr#1674 https://t.co/yMQzt6sU7i

Chimeric autoantigen-T cell receptor (CATCR)-T cell therapies: precision cellular therapy selectively deplete autoreactive B cells @MaxKonigMD in the plenary: CATCR can take out anti-b2GPI autoAbs crucial to antiphospholipid syndrome, but preserve normal B cells #ACR22 @RheumNow https://t.co/5ZLocrwqKY